Rigel posts Q3 2026 profit as VEPPANU launch begins and R289 data head to ASHNov 5Quarterly updateRigel Pharmaceuticals Incvepdegestrant
Boehringer Ingelheim posts Brightline-2 brigimadlin results; BI 4060107 trial recruitsOct 15Weekly roundup, 5 itemsBoehringer Ingelheimempagliflozin
argenx registers Phase 2 trial of empasiprubart for Guillain-Barré syndromeSep 16Trial updateargenxempasiprubart
Annexon reports Q2 2026 results, sets tanruprubart BLA for fourth quarterAug 12Quarterly updateAnnexon, Inc.